Skip to main content
Article thumbnail
Location of Repository

Whole genome association studies of neuropsychiatric disease: An emerging era of collaborative genetic discovery

By Margaret A Keller, Katrina Gwinn, Josefina Nash, Jonathan Horsford, Ran Zhang, Stephen S Rich and Roderick A Corriveau


Family history, which includes both common environmental and genetic effects, is associated with an increased risk for many neuropsychiatric diseases. Investigators have identified several disease-causing mutations for specific neuropsychiatric disorders that display Mendelian segregation. Such discoveries can lead to more rational drug design and improved intervention from a better understanding of the underlying biological mechanisms. However, a key challenge of genetic discovery in human complex diseases, including neuropsychiatric disorders, is that most diseases with genetic components display non-Mendelian patterns of inheritance. Recent advances in human population genetics include high-density genome-wide analyses of single nucleotide polymorphisms (SNPs) that make it possible to study complex genetic contributions to human disease. This approach is currently the most powerful strategy for analyzing the genetics of complex diseases. Genome-wide SNP analyses often require a large collaborative effort to collect, manage, and disseminate the numerous samples and corresponding clinical data. In this review we discuss the use of publicly available biorepositories for the collection and distribution of human genetic material, associated phenotypic information, and their use in genome-wide investigations of human neuropsychiatric diseases

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). Accurate and reliable highthroughput detection of copy number variation in the human genome.
  2. (2005). Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson’s disease.
  3. (2002). and susceptibility to schizophrenia.
  4. (2005). APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
  5. (2006). Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease.
  6. (2006). Copy number variants and pharmacogenomics.
  7. (2006). Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res,
  8. (2006). Detecting copy number variation in the human genome using comparative genomic hybridization.
  9. (2005). Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes.
  10. (1984). Framingham Heart Study: review of genetic data and design, limitations and prospects. Prog Clin Biol Res,
  11. (2005). Gene dosage and pathogenesis of Parkinson’s disease. Trends Mol Med,
  12. (2002). Genetics of parkinsonism.
  13. (2006). Genome assembly comparison identifi es structural variants in the human genome.
  14. (2005). Genome-wide association studies: theoretical and practical concerns.
  15. (2007). Genome-wide association study of prostate cancer identifi es a second risk locus at 8q24. Nat Genet.
  16. (2006). Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: fi rst stage analysis and public release of data.
  17. (2006). Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cellline induced alterations in normal individuals. Hum Mol Genet.
  18. (2006). Global variation in copy number in the human genome.
  19. (1975). Lymphoblastoid transformation and kinetics of appearance of viral nuclear antigen (EBNA) in cord-blood lymphocytes infected by Epstein-Barr Virus (EBV).
  20. (2006). Matrix-assisted laser desorption/ionisation, time-of-fl ight mass spectrometry in genomics research. PLoS Genet,
  21. (2006). Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.
  22. (1993). Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program. Health Serv Res,
  23. (2006). The DDB1-CUL4ADDB2 ubiquitin ligase is defi cient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites.
  24. (2006). Understanding the molecular causes of Parkinson’s disease. Trends Mol Med,
  25. (2006). Variation in retinitis pigmentosa-11 (PRPF31 or RP11) gene expression between symptomatic and asymptomatic patients with dominant RP11 mutations. Hum Mutat,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.